MLL-rearranged acute lymphoblastic leukemia (ALL) in infants is characterized by a poor clinical outcome and resistance to glucocorticoids (for example, prednisone and dexamethasone). As both the response to prednisolone in vitro and prednisone in vivo are predictive for clinical outcome, understanding and overcoming glucocorticoid resistance remains an essential step towards improving prognosis. Prednisolone-induced apoptosis depends on glucocorticoid-evoked Ca 2 þ fluxes from the endoplasmic reticulum towards the mitochondria. Here, we demonstrate that in MLL-rearranged infant ALL, over-expression of S100A8 and S100A9 is associated with failure to induce free-cytosolic Ca 2 þ and prednisolone resistance. Furthermore, we demonstrate that enforced expression of S100A8/S100A9 in prednisolone-sensitive MLL-rearranged ALL cells, rapidly leads to prednisolone resistance as a result of S100A8/S100A9 mediated suppression of prednisolone-induced free-cytosolic Ca 2 þ levels. In addition, the Src kinase inhibitor PP2 markedly sensitized MLL-rearranged ALL cells otherwise resistant to prednisolone, via downregulation of S100A8 and S100A9, which allowed prednisolone-induced Ca 2 þ fluxes to reach the mitochondria and trigger apoptosis. On the basis of this novel mechanism of prednisolone resistance, we propose that developing more specific S100A8/S100A9 inhibitors may well be beneficial for prednisolone-resistant MLL-rearranged infant ALL patients.
INTRODUCTION
Since the early 1960s, treatment results for childhood acute lymphoblastic leukemia (ALL) began to improve steadily and continued to progress ever since. Consequently, the survival chances for childhood ALL, in general, nowadays exceed 85%. 1 Unfortunately, this tremendous step forward has not been equally beneficial for all patients. This is especially true for infants (o1 year of age) with ALL carrying leukemia-specific chromosomal translocations involving the MLL gene, which occur in B80% of the infant ALL cases. 2, 3 Depending on the treatment protocol, survival chances for MLL-rearranged infant ALL patients are at best B40%.
3 Considerably contributing to this poor outcome is cellular resistance to multiple chemotherapeutic drugs, in particular to glucocorticoids like prednisone and dexamethasone, which form the cornerstone of childhood ALL treatment regimes. Prednisolone (the biologically active metabolite of prednisone) dosages needed to eliminate 50% of infant ALL cells in vitro typically are B500 --fold higher than the dosages required to eradicate similar amounts of precursor B-ALL cells from children older than one year of age (that is, non-infants). 4 Moreover, approximately 30% of infants with MLL-rearranged ALL show a poor prednisone response in vivo, compared with only B10% of non-infant pediatric precursor B-ALL cases. 5 As the in vitro prednisolone response and the prednisone response in vivo represent important prognostic factors, 6 --8 the poor prognosis for MLL-rearranged infant ALL seems to a large extent associated with glucocorticoid resistance. Therefore, the mechanism(s) underlying poor glucocorticoid responses should be unraveled in order to adapt treatment strategies and improve prognosis.
We recently demonstrated that high-level expression of the anti-apoptotic BCL-2 family member MCL1 is associated with prednisolone resistance. 9 However, modulation of MCL1 in prednisolone-resistant MLL-rearranged cell line models only resulted in moderate sensitization, 9, 10 implying that other and more relevant resistance mechanisms are involved. In our earlier efforts to define a prednisolone-resistance-associated gene expression profile, the obtained gene signature was compromised by a relatively low accuracy, presumably due to small numbers of patient samples. 9 Recently, however, we published high-resolution gene-expression profiling data on a larger cohort of infant ALL samples, which even allowed specification of differential gene expression between distinct subtypes of infant ALL. 11 Studying these profiles, we observed that MLL-rearranged infant ALL frequently displays high-level expression of genes encoding members of the S100 protein family. For example, S100A10 and S100A4 appeared in the top50 of over-expressed genes in MLLrearranged infant ALL when compared with non-infant pediatric precursor B-ALL. 11 Moreover, a recent paper by Qazi et al. 12 demonstrated that in their gene-expression profiling analyses comparing ALL in infants and non-infants, over-expression of both S100A8 and S100A9 was highly characteristic for infant ALL cells. Intrigued by these observations, we set out to explore the meaning of this phenomenon, and found that the expression of S100 family members often is discriminative between prednisolone-resistant and prednisolone-sensitive MLL-rearranged infant ALL samples. Among other S100 family members, this appeared true for both S100A8 and S100A9. Given that S100A8 and S100A9 form functional heterotetramer protein complexes, 13 --15 we here specifically focused on this particular protein complex in relation to prednisolone resistance. Both S100A8 and S100A9 contain calcium (Ca 2 þ )-binding EF-hand motifs, 16 which provides the S100A8/S100A9-protein complex the capacity to bind, and therefore buffer, free-cytosolic Ca 2 þ . 17 Interestingly, over 30 years ago, Kaiser and Edelmann 18 demonstrated that glucocorticoid-induced lymphocytolysis is dependent on free-cytosolic Ca 2 þ released from the endoplasmic reticulum (ER) upon glucocorticoid exposure. From this, we hypothesized that over-representation of the S100A8/S100A9 complex in the cytosol may establish glucocorticoid resistance in MLL-rearranged ALL by trapping free-cytosolic Ca 2 þ , preventing it to reach the mitochondria, and thereby forestalling apoptosis.
MATERIALS AND METHODS

Patients sample collection and processing
Bone marrow and/or peripheral blood samples from untreated infants (that is, children o1 year of age) diagnosed with MLL-rearranged ALL, were collected at Sophia Children's Hospital (Rotterdam, The Netherlands) as part of the international collaborative INTERFANT-99 treatment protocol. 3 Mononuclear cells were isolated and contaminating non-leukemic cells were removed using immunomagnetic beads as described before. 19 As a result, all leukemic samples used in this study contained 490% of leukemic blasts.
In vitro prednisolone and in vivo prednisone response
In vitro prednisolone sensitivity was assessed by a 4 --day MTT assays as described elsewhere. 20 Patient samples were characterized as in vitro sensitive or resistant to prednisolone based on the LC 50 value (that is, the concentration of prednisolone lethal to 50% of the leukemic cells). Samples were defined as prednisolone-sensitive at LC 50 values o0.1 mg/ml prednisolone, prednisolone intermediate at LC 50 values 0.1 --150 mg/ml, and prednisolone-resistant at LC 50 values 4150 mg/ml prednisolone.
The in vivo response to prednisolone was determined after a 7 --day window of prednisone monotherapy (before the initiation of combination chemotherapy). Patients were defined as prednisone poor responders (PPRs) when 41000 leukemic blasts/l remained present in the peripheral blood. When the amount of leukemic blasts dropped below 1000/l patients were defined as prednisone good responders (PGRs).
RNA extraction and cDNA synthesis Total RNA was extracted from a minimum of 5 Â 10 6 leukemic cells using TRIzol reagent (Invitrogen, Life Technologies, Breda, The Netherlands) according to the manufacturer's guidelines. The quality of the extracted RNA was assessed on 1.5% agarose gels, and the RNA integrity using RNA 6000 Nano Assay LabChips on the Agilent 2100 Bio-analyzer (Agilent Technologies, Santa Clara, CA, USA). Further cDNA synthesis was performed as described previously. 21 Microarray and bioinformatics analyses Gene-expression profiles (Affymetrix HGU133plus2.0. GeneChips) were generated for primary MLL-rearranged infant ALL samples to produce an in vitro prednisolone resistance signature. The gene-expression data has been deposited in the NCBI Gene Expression Omnibus under the GEO Series accession number GSE32962. For the analysis of differentially expressed genes between prednisolone sensitive and resistant patients, raw microarray data (Affymetrix HU133plus2.0 GeneChips) were collectively normalized using variance-stabilizing normalization (VSN), 22 and differential gene expression was statistically evaluated using linear models for microarray analyses. 23, 24 A detailed description of the processing of RNA samples and the generation of the gene expression profiles are previously described elsewhere. Gene-set enrichment analysis 25 was used to evaluate enrichment of genes encoding S100 protein family members in prednisolone-resistant MLL-rearranged infant ALL samples. Supplementary Table 1 lists the gene enrichment scores for all S100 family members.
Quantitative real time PCR analysis S100A8 and S100A9 mRNA expression was quantified by quantitative realtime PCR analysis 26 using the DyNAmo SYBR Green qPCR kit (Finnzymes, Espoo, Finland). Oligonucleotide primers used for PCR amplification were designed using the OLIGO 6.22 software (Molecular Biology Insights, Cascade, CO, USA) and purchased from Eurogentec (Seraing, Belgium). Primer sequences were as follows: sense strand: 5'-GTGGGCATCATGTTGAC-3 0 and antisense strand: 5 0 -TGCACCATCAGTGTTGATA-3 0 (for S100A8); sense strand: 5 0 -TCGGCTTTGACAGAGTG-3 0 and anti-sense strand: 5 0 -GGTCCT CCATGATGTGTT-3 0 (for S100A9); sense strand: 5 0 -GTCGGAGTCAACGGATT-3 0 and anti-sense strand: 5 0 -AAGCTTCCCGTTCTCAG-3 0 (for GAPDH; used as a reference gene). Supplementary Table 2 lists the primer sequences used for the other S100 genes.
Cell culturing and flow cytometry
The leukemia cell lines RS4;11, BEL-1, SEM (ALL cell lines) and MV4-11 (acute myeloid leukemia (AML) cell line) all carry the MLL translocation t(4;11) generating the MLL-AF4 fusion protein, and were maintained in RPMI 1640 with glutamax (Invitrogen, Life Technologies) supplemented with 10% (v/v) FCS and 1% penicillin/streptomycin/fungizone (PSF; Invitrogen, Life Technologies) at 37 1C in humidified air-containing 5% CO 2 . RS4;11 and BEL-1 represent in vitro prednisolone-sensitive cell lines, whereas SEM and MV4-11 are in vitro prednisolone-resistant. Depending on the experiments, cell lines were cultured in the presence of prednisolone (25 mg/ml; Bufa, Uitgeest, The Netherlands), EGTA (50 mM; Sigma, St Louis MO, USA), BAPTA-AM (2 mM; Sigma) or PP2 (4 --amino-5 --4 --chlorophenyl)-7 --t-butyl) pyrazolo 27 pyrimidine; 10 mM; Sigma) even before in vitro cytotoxicity testing. Free-cytosolic Ca 2 þ was stained using Calcium Green-1 (Invitrogen, Life Technologies) and measured on a flow cytometer (Facs Calibur, Becton Dickinson, Franklin Lakes, NJ, USA). For this, leukemic cells were washed twice in phosphate-buffered saline and incubated with 2 mM of Calcium Green-1 for 1 h at RT in the dark. Before detection by flow cytometry, incubated cells were washed twice in phosphate-buffered saline to exclude a specific binding Calcium Green-1. Similarly, mitochondrial depolarization was detected using JC-1, a cationic dye that displays potential-dependent accumulation in the mitochondria, indicated by a fluorescence emission shift from green to red.
Western blotting
Western blot analysis was performed as described previously. 28 Briefly, cellular proteins were resolved on the polyacrylamide gels and transferred to nitrocellulose membrane. Membranes were probed using mouse monoclonal antibodies against human S100A8 and rabbit polyclonal antibodies against human S100A9 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Anti-actin mouse monoclonal antibodies (Sigma-Aldrich) were used to confirm equal loading in all lanes.
Transfection of leukemia cell lines with S100A8-and S100A9-expressing constructs Full-length cDNA of human S100A8 and S100A9 were cloned into mammalian expression vectors: S100A8 into pLPCX containing a puromycin selection marker (Clontech, Mountain View, CA, USA) and S100A9 into pLNCX2 containing a neomycin selection marker (Clontech). The primer sequences used to amplify the entire coding regions of these genes were as follows: sense strand: 5 0 -TGTCAGCTGTCTTTCAGAAG-3 0 and anti-sense strand: 5 0 -TGGGCCCAGTAACTCA-3 0 for S100A8; sense strand: 5 0 -CTCGGCTTTGACAGAGTG-3 0 and anti-sense strand: 5 0 -CTGGCCTCCTGAT TAGTG-3 0 for S100A9. S100A8 was cloned into pLPCX using the restriction enzymes HindIII and NotI. The same enzymes were used to insert S100A9 into pLNCX2. Next, prednisolone-sensitive RS4;11 cells were transfected with S100A8 pLPCX or S100A9 pLNCX2 constructs by square-pulse electroporation (at 600 V, for 2 msec). Cells transfected with the constructs were cultured under selection of neomycin (1 mg/ml; Gibco BRL, Life Technologies, Grand Island, NY, USA) and puromycin (10 mg/ml; Sigma) in order to obtain a pure population of transfected cells.
Statistical analysis
Differences in S100 gene expression between patients groups or cell lines were statistically evaluated using the Mann --Whitney U-test. The student t-test or the one-way analysis of variance test was used to analyze differences in mean cytotoxicity responses and to determine differences in mitochondrial membrane depolarization. All analyses were two-tailed, and differences were considered statistically significant at P-values o0.05 (indicated in experiments with asterisks). Spearman's Rho test was used to assess the correlation between VSN normalized expression of S100A9 and VSN normalized expression of S100A8 or MCL-1. Log-rank test was performed to analyze differences in outcome between patient groups expressing high and low levels of S100A8 and S100A9.
RESULTS
High-level S100A8/S100A9 expression in prednisolone-resistant MLL-rearranged infant ALL In order to gain more insight into the mechanisms that underlie prednisolone resistance in MLL-rearranged infant ALL, we continuously search for genes that are differentially expressed in prednisolone-resistant and prednisolone-sensitive patient samples. For this, in vitro response to prednisolone is assessed by 4-day cytotoxicity (MTT) assays, and the LC 50 values (that is, the concentration of prednisolone required to eliminate 50% of the leukemic cells) are used to determine prednisolone sensitivity. Patient samples are deemed sensitive at LC 50 values of o0.1 mg/ml of prednisolone, and resistant at LC 50 values of 4150 mg/ml. Next, high-resolution gene-expression profiling data (Affymetrix HU133plus2.0 microarrays) is used to evaluate differential gene expression between prednisolone-resistant and -sensitive primary MLL-rearranged infant ALL samples. Remarkably, applying this approach, we often encountered differentially expressed genes encoding members of the S100 protein family. Although these genes do not represent the most significant genes discriminating between prednisolone-resistant and -sensitive patients, gene-set enrichment analysis revealed pronounced enrichment of high-level expression of multiple S100 family members in prednisolone-resistant MLL-rearranged infant ALL samples (Figure 1a and Supplementary Table 1) . Therefore, we studied VSN-normalized gene expression (Affymetrix HU133plus2 microarray data) for all probe sets corresponding to S100 genes in infant and non-infant pediatric B-ALL samples. In general, all genes encoding evaluated members of the S100 protein family appeared to be consistently expressed at higher levels in infant ALL cells as compared with pediatric precursor B-ALL cells from children older than 1 year of age, with the exception of S100A13 (Figure 1b) . Moreover, comparing MLLrearranged infant ALL samples, either resistant or sensitive to prednisolone, demonstrated that S100 expression often is higher in prednisolone-resistant samples (Figure 1b) . Although the strongest enrichment in prednisolone-resistant MLL-rearranged infant ALL samples was observed for S100A11, S100A2 and S100P (Supplementary Table 1 ), the expression levels of these particular genes were rather low when compared with, for example, S100A8 and S100A9 (Figure 1b) . In addition, studying the differences in expression of S100-encoding genes between prednisoloneresistant and -sensitive MLL-rearranged leukemia cell lines (Figure 1c) showed that the largest fold-change was observed for S100A8 (Figure 1d) . Given that the expression of these two S100 family members appeared extremely high in MLLrearranged infant ALL patient samples, and show pronounced differences in expression between prednisolone-resistant and -sensitive cases (Figure 1b) , and displayed the highest enrichment after S100A11, S100A2 and S100P (Supplementary  Table 1) , we decided to further focus on S100A8 and S100A9. Further supporting our choice to here focus on these to particular members of the S100 protein family is the fact that, at the protein level, S100A8 and S100A9 preferably function cooperatively in heterotetramer complexes. 13 --15 To validate our gene-expression data, quantitative real-time PCR analysis was performed using primer sets specifically amplifying either S100A8 or S100A9. This confirmed that prednisoloneresistant patients expressed 4100-fold higher levels of both S100A8 and S100A9 compared with prednisolone-sensitive patients. Moreover, patients displaying intermediate in vitro sensitivity to prednisolone (LC 50 values of 40.1 and o150 mg/ ml) exhibit intermediate S100A8 and S100A9 expression levels (Figures 2a and b) . Of note is that the S100A8 and S100A9 expression levels, as determined by quantitative real-time PCR analysis, appeared to be exceedingly high. Whereas the majority of genes are expressed at relative levels of B0.5 --5% of the housekeeping gene GAPDH, in prednisolone-resistant MLL-rearranged infant ALL cells the expression levels of both S100A8 and S100A9 appeared near comparable to that of GAPDH.
As both the in vitro prednisolone response, as well as the in vivo prednisone response, have been shown to be predictive for clinical outcome, 6 --8 we next asked whether the observed correlation between high-level S100A8/S100A9 expression and resistance to prednisolone also holds true for the in vivo prednisone response. As part of the INTERFANT-99 treatment protocol, 3 infant ALL patients receive prednisone monotherapy before initiation of combination chemotherapy. After 7 days, the drop in leukemic blasts in the peripheral blood reflects the in vivo prednisone response, and is used to ascribe patients to either the standard-risk (PGRs) or the high-risk (PPRs) arm of the treatment protocol. To evaluate how the S100A8/S100A9 expression correlates with the in vivo prednisone response, we plotted the distribution of S100A8 and S100A9 expression between PGRs and PPRs. As shown in Figure 2c , patients showing an in vivo PPR are clearly expressing higher levels of both S100A8 and S100A9. However, statistical analysis showed that these differences did not reach significance, presumably due to a few patients in the PPRgroup expressing low S100A8/S100A9 levels. Together, this suggests that in general the correlation between high-level S100A8 and S100A9 expression and both the in vitro prednisolone and in vivo prednisone response exists, but also implies that in some patients other (presumably pharmacodynamical) mechanisms have a role.
High-level S100A8/S100A9 expression in MLL-rearranged infant ALL is associated with a poor prognosis Expression of several S100 family members, including S100A8 and S100A9, have been shown to correlate with an adverse prognosis in invasive ductal carcinomas of the breast 29 and in de novo pediatric AML patients. 30 Likewise, low S100A8 and S100A9 expression has been shown to correlate with a good prognosis in childhood AML patients carrying IDH1/2 mutations. 31 Therefore, we asked whether high-level S100A8 and S100A9 expression is also associated with a poor prognosis in MLL-rearranged infant ALL. For this, we divided patient samples into two groups either expressing high or low levels of S100A8 and S100A9 based on our quantitative RT-PCR data, using the median S100A8/S100A9 expression levels as cut-off values. Interestingly, the event-free survival varied significantly between both the subgroups (Po0.05), with MLLrearranged ALL patients expressing high-level S100A8 and S100A9 expression being at extreme high risk of disease relapse or other complications during treatment, whereas patients expressing low-levels of S100A8 and S100A9 seem to be fare markedly better (Figure 3 ).
Multiple studies identified the in vivo prednisone response as a prognostic marker for MLL-rearranged infant ALL. 6 However, despite clear trends towards a correlation between high-level S100A8/S100A9 expression and the in vivo prednisone response (Figure 2c ), these differences did not reach significance. Therefore, we also determined clinical outcome between patients showing a good or a poor prednisone response in vivo (Figure 3) . Remarkably, although PPRs showed a worse Figure 1 . Enrichment and distribution of the expression of the S100 gene family in prednisolone-resistant MLL-rearranged infant ALL samples. (a) Gene-expression profiling data (Affymetrix HU133plus2 GeneChips) associated with in vitro prednisolone resistance in primary MLLrearranged infant ALL samples was used for gene-set enrichment analysis interrogating enrichment of the entire S100 gene family. As shown in the enrichment plot, high-level S100 expression appears highly associated with resistance to prednisolone (Po0.05). (b) VSN-normalized gene expression of all members of the S100 gene family is depicted for childhood (41 year of age) precursor B-ALL (black boxes), infant (o1 year of age) ALL including both MLL-rearranged and wild-type MLL cases (white boxes), prednisolone-resistant MLL-rearranged infant ALL (horizontally striped boxes), and prednisolone-sensitive MLL-rearranged infant ALL (vertically striped boxes). VSN expression values of o3.5 imply very low to no expression and coincide with the background noise. (c) In vitro prednisolone responses in the MLL-rearranged leukemia cell lines BEL-1, RS4;11 (prednisolone-sensitive), and SEM and MV4-11 (prednisolone-resistant). (d) Shows the fold-change in mRNA expression of S100 genes in MLL-rearranged in vitro prednisolone-sensitive cell lines (RS4;11 and BEL-1) compared with in vitro prednisoloneresistant cell lines (SEM and MV4-11). Fold-change expression of S100 genes in the resistant cell lines was normalized to the expression in of the same genes in the sensitive cell lines. S100 genes that are upregulated in resistant cell lines are depicted in black, and downregulated genes are depicted in gray. Differences in S100 expression were statistically analyzed using the Mann --Whitney U-test; *indicates significant differences with P-values of o0.05. outcome than PGRs, the level of S100A8 and S100A9 expression appeared to be a much stronger predictor of prognosis in these patients.
Prednisolone sensitivity is dependent on prednisolone-induced Ca 2 þ release Already in 1977, Kaiser and Edelmann 18 showed that glucocorticoid-induced lymphocytolysis requires cytosolic Ca 2 þ which is released from the ER upon glucocorticoid exposure. 32 --34 Given the Ca 2 þ -binding properties of the S100A8/S100A9 protein complex 26 --28 and the association of high-level S100A8/S100A9 expression with prednisolone resistance, we set out to explore the importance of Ca 2 þ release in prednisolone-induced apoptosis in MLL-rearranged ALL cells. For this, the levels of free-cytosolic Ca 2 þ were determined in prednisolone-sensitive and prednisolone-resistant MLL-rearranged leukemia cell line models using flow cytometry. These analyses showed that in MLL-rearranged leukemia cell lines that are sensitive to prednisolone in vitro, pronounced levels of prednisolone-induced free-cytosolic Ca 2 þ are detectable (Figure 4a ). In contrast, in prednisolone-resistant MLL-rearranged leukemia cell lines, the levels of free-cytosolic Ca 2 þ were hardly elevated upon prednisolone exposure (Figure 4a) .
To confirm that prednisolone-induced apoptosis depends on free-cytosolic Ca 2 þ , sensitive cells were exposed to prednisolone either in the absence or presence of the Ca 2 þ chelators EGTA (50 mM) or BAPTA-AM (2 mM), that have been shown to effectively scavenge free-cytosolic Ca 2 þ . Both EGTA and BAPTA-AM fully inhibited prednisolone-induced Ca 2 þ release within 4 h of exposure ( Figure 4b) . As a consequence, both EGTA and BAPTA-AM to some extent induced resistance to prednisolone in otherwise sensitive MLL-rearranged ALL cells, albeit the effects for both co-incubations appear moderate in 2-day cytotoxicity assays (Figures 4c and d) . Moreover, the effects of BAPTA-AM-and EGTA-induced inhibition of free-cytosolic Ca 2 þ on prednisolone sensitivity seems to vary between both cell lines tested. A plausible explanation for this variability as well as for the moderate effects on prednisolone cytotoxicity is the fact that optimal inhibition of free-cytosolic Ca 2 þ by BAPTA-AM and EGTA takes place at 4 h of exposure, but after that rapidly diminishes. As in vitro prednisolone sensitivity is here determined in 2-day MTT assays, the effects of BAPTA-AM and EGTA largely depend on Ca 2 þ inhibition during the first 4 h of the cytotoxicity assay. Nevertheless, these results clearly demonstrate that short-term inhibition of free-cytosolic Ca 2 þ certainly affected the in vitro prednisolone response in otherwise highly sensitive cells. Figure 2 . High-level S100A8/S100A9 expression is correlated with in vitro prednisolone resistance and a poor prognosis in MLLrearranged ALL. Relative mRNA expression of (a) S100A8 and (b) S100A9 as determined by quantitative real-time PCR analysis in an independent cohort of MLL-rearranged infant ALL patient samples either in vitro sensitive (n ¼ 5) or resistant (n ¼ 5) to prednisolone, and in patients displaying intermediate responses (n ¼ 5). (c) Relative S100A8 and S100A9 mRNA expression in MLL-rearranged infant ALL patients based on the in vivo prednisone response. PGR (n ¼ 9), PPR (n ¼ 4). Figure 3 . S100A8/S100A9 expression and clinical outcome. Event-free survival for MLL-rearranged infant ALL patients expressing high (n ¼ 6) or low (n ¼ 8) levels of S100A8/S100A9. The median expression value in the entire cohort was used as the cut-off value in order to divide the two patient groups (in black). Event-free survival for MLLrearranged infant ALL patients, displaying in vivo PGR (n ¼ 9) or PPR (n ¼ 4) (in gray). Differences in outcome were statistically analyzed using the log-rank test.
High-level S100A8/S100A9 expression inhibits free-cytosolic Ca 2 þ and induces prednisolone resistance With the above confirmation that prednisolone-induced apoptosis requires free-cytosolic Ca 2 þ , we hypothesized that the observed over-representation of both S100A8 and S100A9 obstruct prednisolone-induced apoptosis by binding and thereby preventing cytosolic Ca 2 þ released from the ER. To test this, prednisolone-sensitive MLL-rearranged ALL cells were transduced with eukaryotic expression vectors encoding human S100A8 and/or S100A9 and free-cytosolic Ca 2 þ levels measured upon prednisolone exposure. The transfection experiments resulted in pronounced upregulation of both genes as determined by quantitative RT-PCR analysis (*Po0.05) (Figure 5a ). Prednisolone-induced Ca 2 þ release was partially inhibited in cells transduced with S100A8 or S100A9 alone, whereas no free-cytosolic Ca 2 þ was detected in cells overexpressing both S100A8 and S100A9 (Figure 5b ). In line with this, prednisolone-sensitive MLL-rearranged ALL cells transduced , after 4 h incubation with prednisolone (25 mg/ml). In vitro prednisolone response for (c) RS4;11 and (d) BEL-1 in the absence or presence of either EGTA (50 mM) or BAPTA-AM (2 mM), as determined by 2-day MTT assays. *Significant differences at P-values of o0.05, and ** Po0.005.
with either S100A8 or S100A9 separately became somewhat more resistant to prednisolone resulting in increase of leukemic cell survival of B30 --40% (Figure 5c ). However, when transduced with both S100A8 and S100A9 simultaneously, the prednisolone-sensitive MLL-rearranged ALL cells became highly resistant to prednisolone (*Po0.05) (Figure 5c ).
Mitochondrial depolarization is inhibited by S100A8 and S100A9 Free-cytosolic Ca 2 þ rapidly migrates towards the mitochondria and successively leads to the depolarization of the mitochondrial membrane, cytochrome c release from the mitochondria, the formation of the apoptosome, and the initiation of apoptosis. 35 --38 As proposed in the present study, high-level expression of S100A8 and S100A9 prevent cytosolic Ca 2 þ to reach to the mitochondria. Thus, transfection of prednisolonesensitive MLL-rearranged ALL cells with both S100A8 and S100A9 should lead to an unaffected mitochondrial membrane potential when these cells are exposed to prednisolone. Therefore, the prednisolone-sensitive MLL-rearranged ALL cell line RS4;11 was transduced with S100A8 and/or S100A9 and incubated with prednisolone (25 mg/ml). Subsequently, the mitochondrial potential was measured using flow cytometry. Mitochondrial depolarization was indeed observed in prednisolone-sensitive cells transduced with empty vectors (*Po0.05), whereas the mitochondrial membrane potential remained unaffected in cells over-expressing S100A8 and/or S100A9 after prednisolone exposure (Figure 5d ). Figure 5 . S100A8/S100A9 over-expression depletes free-cytosolic Ca 2 þ and induces prednisolone resistance in MLL-rearranged ALL cells. (a) Quantitative real-time PCR analysis showing the mRNA expression of S100A8 or S100A9 in the prednisolone-sensitive cell line RS4;11 transduced with eukaryotic expression vectors encoding human S100A8 and/or S100A9. (b) Measurement of prednisolone-induced freecytosolic Ca 2 þ in prednisolone-sensitive RS4;11 cells after transduction with vectors enforcing S100A8 and/or S100A9 expression or with empty vectors (controls). Inserts represent the shift in free-cytosolic Ca 2 þ compared with untransduced cells. (c) In vitro prednisolone response of prednisolone-sensitive RS4;11 cells in the absence and presence of enforced S100A8 and/or S100A9 expression. (d) Mitochondrial depolarization analysis in RS4;11 cells before and after transfection with eukaryotic expression vectors encoding S100A8 and/or S100A9, when challenged with prednisolone (25 mg/ml) for 24 h.
Inhibition of S100A8 and S100A8 by PP2 induces prednisolone sensitivity in prednisolone-resistant MLL-rearranged ALL cells Next, we asked whether inhibition of the S100A8/S100A9 protein complex leads to sensitization to prednisolone in resistant MLLrearranged ALL cells expressing high levels of S100A8 and S100A9. In a recent paper, Ryckman et al. 39 showed that the Src kinase inhibitor PP2 (4 --amino-5 --4 --chlorophenyl)-7 --t-butyl) pyrazolo-3,4 --d-zpyrimidine) was able to inhibit S100A8/S100A9 release from neutrophils by approximately 50%. On the basis of these findings, we investigated the potential of PP2 to sensitize prednisolone-resistant MLL-rearranged ALL cells. Co-incubation of 10 mM of PP2 with prednisolone in prednisolone-resistant MLLrearranged ALL cell line SEM indeed showed sensitization to prednisolone (Figure 6a ), whereas no additional sensitization for prednisolone occurred in in vitro prednisolone-sensitive cell line RS4;11 (Figure 6b) . Importantly, PP2-induced prednisolone sensitivity in MLL-rearranged cells was accompanied by detectable levels of cytosolic Ca 2 þ in response to prednisolone exposure (Figure 6c) , and downregulation of both S100A8 and S100A9 at the protein level (Figures 6d and e) . Although the levels of free-cytosolic Ca 2 þ were apparently not increased at 10 mM, of PP2, it must be taken into consideration that the detection of free-cytosolic Ca 2 þ is performed after 4 h of exposure, whereas in vitro prednisolone cytotoxicity was assessed in 4-day MTT assays. Measurements of free-cytosolic Ca 2 þ at increasing concentrations of PP2, show that PP2 exposure indeed results in increased levels of free-cytosolic Ca 2 þ (already after 4 h of exposure) when cells are challenged with prednisolone.
Interestingly, the sensitizing effects of PP2 were only observed for the glucocorticoids prednisolone and dexamethasone, but not for other therapeutics used in the treatment of childhood ALL such as L-asparaginase, vincristine, daunorubicin, cytarabine (Ara-C) or cladribine (2CdA) (Supplementary Figure 1) .
DISCUSSION
Cellular resistance to the glucocorticoids prednisone and dexamethasone is a major obstacle in reaching successful treatment results for MLL-rearranged infant ALL. Glucocorticoids induce apoptosis by releasing Ca 2 þ from the endoplasmic reticulum (ER; Ca 2 þ storage), which was first demonstrated by Kaiser and Edelmann 18 who showed that glucocorticoid-induced lymphocytolysis is correlated with a higher Ca 2 þ influx. These findings were later confirmed by McConkey et al. 40 who showed that Shows western blot analysis of the protein expression of S100A8 and S100A9 in SEM cells upon exposure to PP2 (10 mM) at indicated time points. (e) Depicts the calculated ratios of S100A8 or S100A9 protein expression normalized against actin expression in these samples in the absence or presence of 10 mM of PP2.
prednisolone-induced apoptosis in thymocytes also depends on the release of free Ca 2 þ into the cytosol. Subsequently, freecytosolic Ca 2 þ migrates towards the mitochondria. Mitochondrial Ca 2 þ uptake results in opening of the permeability transition pore and in depolarization of the mitochondrial membrane. 36, 37 In turn, disruption of the mitochondrial membrane induces apoptosis by the release of cytochrome c and apoptosis-inducing factor, resulting in activation of the downstream caspase cascade. 35, 38 Thus, hindered migration of prednisolone-induced cytosolic Ca 2 þ towards the mitochondria, for example, by Ca 2 þ -binding proteins may well cause prednisolone resistance. Here, we show that in prednisolone-resistant MLL-rearranged infant ALL, high-level expression of S100A8 and S100A9 is associated with resistance to glucocorticoid-induced apoptosis. Given the Ca 2 þ -binding capacity of the S100A8/A9 protein complex, it may be tempting to assume that these complexes simply act as Ca 2 þ chelators, binding all or most of the Ca 2 þ ions released into the cytosol. Although the here-observed S100A8 and S100A9 mRNA levels in primary prednisolone-resistant MLL-rearranged infant ALL samples appeared extremely high and comparable to the level of expression of the housekeeping gene GAPDH, it remains uncertain and perhaps unlikely that the Ca 2 þ -binding capacity of S100A8/ A9 is sufficient to absorb all Ca 2 þ released into the cytosol. Additional or alternative mechanisms may therefore not be excluded. For instance, S100A8/S100A9 may exert direct inhibitory effects on the release mechanisms of cellular Ca 2 þ stores, effectively blocking Ca 2 þ release at its source without the necessity of binding high concentrations of free-cytosolic Ca 2 þ . In the present study, as we measured the levels of free-cytosolic Ca 2 þ in the presence or absence of high-level S100A8/A9 expression, these experiments do not reveal whether free-cytosolic Ca 2 þ is actually bound by S100A8/A9 complexes, or whether cytosolic Ca 2 þ release is blocked before reaching the cytosol. As the dismal prognosis of MLL-rearranged infant ALL seems tightly linked to cellular resistance to glucocorticoids, unraveling the underlying resistance mechanisms represents an important step toward improved prognosis. Recently, we showed that MLLrearranged infant ALL cells that are in vitro resistant to prednisolone express high levels of the anti-apoptotic BCL2 family member MCL1.
9 Although MCL1 knock-down experiments in prednisolone-resistant MLL-rearranged leukemia cells demonstrated a clear but modest induction of prednisolone sensitivity in these cells, 9 it remained speculative whether elevated MCL1 expression embodied the most important mechanism of resistance. Interestingly, Minagawa et al. 41 showed how MCL1 obstructs apoptosis by inhibiting mitochondrial Ca 2 þ levels. As such, MCL1 is able to delay Ca 2 þ -induced apoptosis, however, when repetitive Ca 2 þ signals reach certain thresholds, MCL1 is not able to prevent apoptosis. 42 From the perspective of Ca 2 þ -dependence in glucocorticoid-induced apoptosis, high-level MCL1 expression represents a rather downstream line of defense. As shown in the present study, elevated levels of S100A8/S100A9 appear to already inhibit prednisolone-induced Ca 2 þ levels in the cytosol, providing yet another and more upstream defense mechanism against glucocorticoid-induced cell death. If so, high-level MCL1 expression only becomes relevant in case S100A8/S100A9 expression is low. Interestingly, we found a strong correlation between S100A8 and S100A9 expression, but a correlation between S100A8/S100A9 and MCL1 expression appeared completely absent (Figure 7a ). Supposedly, high-level MCL1 only becomes protective against prednisolone-induced apoptosis when the levels of S100A8/S100A9 are not high enough to suppress sufficient amounts of free Ca 2 þ released by the ER in response to glucocorticoid exposure. Emphasizing this is our observation that MLL-rearranged infant ALL cells expressing highlevels of S100A8 and S100A9 are in vitro resistant to prednisolone regardless the level of MCL1 expression (Figure 7b) . Only when the level of S100A8/S100A9 expression is low, MCL1 expression levels become discriminative for the in vitro prednisolone response (Figure 7b ). Together, these findings explain that, as shown before, high-level MCL1 expression is to some extent associated with prednisolone resistance 9 but that MCL1 knock-down or inhibition may not be sufficient to completely reverse the prednisoloneresistant phenotype in MLL-rearranged ALL. In contrast to MLLrearranged infant ALL, high-level S100A8/S100A9 expression appeared largely absent in other types of childhood ALL (Figure 1b) , suggesting that the inhibition of MCL1 in prednisolone resistant non-infant pediatric precursor B-ALL cells may be far more effective. 9, 10 Furthermore, we show that high-level expression of S100A8 and S100A9 is not only associated with in vitro prednisolone resistance, but also correlates (although not significantly) with poor in vivo prednisone responses. Interestingly, the level of S100A8/A9 expression appeared a stronger predictor of a poor clinical outcome than the in vivo prednisone response. This may either indicate that S100A8/A9 expression more accurately discriminates between favorable or poor responses to glucocorticoid-based therapies, or implies that the S100A8/S100A9 protein complex exerts additional functions contributing to the aggressive nature of MLL-rearranged ALL. In line with this, low expression of S100A8 and S100A9 was recently reported to represent a predictor of a Figure 7 . Correlation of MCL-1 to S100A8/S100A9 in MLL-rearranged infant leukemia. (a) Correlation between VSN-normalized expression (Affymetrix HU133plus2 microarray data) of S100A9 (x-axes) to S100A8 or MCL-1 (y-axes) in primary MLL-rearranged infant ALL samples (n ¼ 57). (b) In vitro cytotoxicity for prednisolone as determined by 4-day MTT assays in MLL-rearranged infant ALL, expressing high or low levels of S100A8/S100A9 in combination with either high or low levels of MCL1. For each gene, the median expression level in the entire patient cohort was used as the cut-off value to distinguish between high or low level expression.
good prognosis in IDH1/2-mutated childhood AML patients. 31 Similarly, Nicolas et al. 30 demonstrated that high-level expression S100A8 represents poor prognostic marker in de novo pediatric AML. In concordance, our data shows that high-level S100A8/ S100A9 expression not only correlates with glucocorticoid resistance, but in itself seems to accurately predict an inferior outcome in MLL-rearranged infant ALL. As high-level S100A8/ S100A9 expression has been associated with tumor development, invasion, and metastasis in several types of human cancers, 43 a role in MLL-fusion-driven leukemogenesis might be plausible, at least in a subset of MLL-rearranged infant ALL patients.
In any case, the present study demonstrates that the S100A8/ S100A9 protein complex represents an attractive target for therapeutic intervention in order to improve the response to glucocorticoids and with that improve the prognosis for MLLrearranged infant ALL. As shown, the Src kinase inhibitor PP2 to some extent targets and downregulates the S100A8/A9 complex, and sensitizes otherwise resistant MLL-rearranged ALL cells to prednisolone. Obviously, PP2 does not represent a highly specific S100A8/S100A9 inhibitor, as the compound was designed to target a broad spectrum of Src kinase family members. 44 Additional influences of Src kinase inhibition on prednisolone resistance can therefore not be excluded. Also, S100A8 and S100A9 may not be the only S100 family members targeted by this inhibitor, as PP2 was recently shown to also inhibit S100A4 expression in colon carcinomas. 45 From this perspective, the development of more specific S100A8/S100A9 inhibitors that are able to reverse the prednisolone-resistant phenotype in MLL-rearranged infant ALL may be desirable. For example, small molecules that prevent the formation of the S100A8/S100A9 heterodimeric complex, or that block the Ca 2 þ -binding sites in these proteins, could potentially diminish its suppressive actions on prednisolone-induced Ca 2 þ release, and allow apoptosis. The development of such compounds represents a potentially attractive challenge providing new therapeutic options for MLL-rearranged ALL, and possibly for other human malignancies as well.
